Eric K. Rowinsky Joins ADVENTRX Board of...( SAN DIEGO Feb. 25 /- ADVENTRX Pha...)

SAN DIEGO, Feb. 25 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that Eric K. Rowinsky, M.D., Chief Medical Officer and Executive Vice President of ImClone Systems Incorporated, will join its Board of Directors. In connection with Dr. Rowinsky's appointment, ADVENTRX increased the size of its Board from six to seven directors.

"We are delighted to welcome Eric to our Board of Directors. He brings tremendous knowledge and expertise within the oncology field," stated Evan M. Levine, ADVENTRX's Chief Executive Officer and President. "We believe his experience will be an important asset as we advance our product candidates through the clinic," added Mr. Levine.

"I'm very pleased to be joining ADVENTRX's Board of Directors," commented Dr. Rowinsky. "I hope my contributions help advance the development and commercialization of the Company's product candidates, which hold significant potential to provide patients with better treatment options."

Prior to joining ImClone Systems in 2005, Dr. Rowinsky focused his academic efforts in cancer drug development as the Director of Clinical Research and later Director of the Institute for Drug Development of the Cancer Therapy and Research Center in San Antonio and the SBC Endowed Chair for Early Drug Development from 1996 to 2005. He was also Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio from 1996 to 2006. From 1987 to 1996, Dr. Rowinsky served as an Associate Professor of Oncology at the Johns Hopkins University School of Medicine. He was a longstanding NCI principal investigator on U01 anticancer drug development grants and integrally involved in pivotal clinic
'/>"/>